Advanced search
Publication Cover
Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders Volume 5, 2004 - Issue 2
Journal homepage
207
Views
97
CrossRef citations to date
0
Altmetric
Article

Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials

Vincent Meininger Division MazarinCorrespondence[email protected]‐hop‐paris.fr
,
Gilbert Bensimon  
,
Walter G Bradley Division Ambroise Pare, Service de Pharmacologie Clinique du Professeur Lechat, Groupe Hospitalier Pitié Salpétrière, 47‐83, Bd. de l'Hôpital, 75651 Paris Cedex 13, France
,
Benjamin R Brooks Department of Neurology, University of Miami School of Medicine (M712), PO Box 016990, Miami, Florida 33101, USA
,
Patrice Douillet University of Wisconsin, ALS Clinical Research Center, J6/504 Clinical Science Center, 600 Island Av, Madison, Winsconsin 53792‐5132, USA
,
Andrew A Eisen Sanofi‐Synthélabo Recherche, 371, rue du Prof. Blayac, 34184 Montpellier Cedex 4, France
,
Lucette Lacomblez Vancouver Hospital, Neuromuscular Diseases Unit, 855 West 12th Avenue, Vancouver, British Columbia, V5Z 1M9 Canada
,
P Nigel Leigh Department of Neurology, Institute of Psychiatry, King's College London, De Crespigny Park, Denmark Hill, London SE5 8AF, U.K
&
Wim Robberecht Department of Neurology, University Hospital Gasthuisberg, 3000 Leuven, Belgium
 show all
Pages 107-117 | Published online: 10 Jul 2009

References

  • Leigh PN. Pathogenic mechanisms in amyotrophic lateral sclerosis and other motor neuron disordersIn: Calne DB, ed. Neurodegenerative Diseases. Philadelphia, PA: WB Saunders and Co. 1994: 473–488.
  • Swash M, Schwartz MS. Motor neuron disease: the clinical syndrome. In: Leigh PN, Swash M, eds. Motor Neuron Disease: Biology and ManagementLondon: Springer Verlag 1995: 1–17.
  • Tysnes OB, Vollet SE, Larsen TP, Aarli JA. Prognostic factors and survival in amyotrophic lateral sclerosisNeuroepidemiol 1994; 13: 226–235.
  • Lacomblez L, Bensimon G, Leigh PN, Guillet P. Meininger V for the Amyotrophic lateral sclerosis/riluzole Study Group II. Dose- ranging study of riluzole in amyotrophic lateral sclerosisLancet 1996; 347: 1425–1431.
  • Bensimon G, Lacomblez L, Meininger V, and the ALS/riluzole study group. A controlled trial of riluzole in amyotrophic lateral sclerosisN Engl J Med 1994; 330: 585–591.
  • Miller RG, Mitchell JD, Lyon M, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) (Cochrane Review)In: The Cochrane Library, Issue 3. Oxford: Update Software (2002).
  • Fournier J, Keane PE, Ferrara P, Soubrie´ P. SR57746A: An orally active non-peptide compound with neuroprotective and neuro- trophic effectsCNS Drug Reviews 1997; 3: 148–167.
  • Labie C, Lafon C, Marmouget C et al. Effect of the neuropro- tective compound SR57746A on nerve growth factor synthesis in cultured astrocytes from neonatal rat cortexBr J Pharmacol 1999; 127: 139–144.
  • Duong F, Fournier J, Keane PE et al. The effect of the nonpeptide neurotrophic compound SR57746A on the progression of the disease state of the pmn mouseBr J Pharmacol 1998; 124: 811–817.
  • Lacomblez L, Bensimon G, Douillet P, Doppler V, Salachas F, Meininger V. Xaliproden in amyotrophic lateral sclerosis: over- view about the early clinical development programme and main resultsAmyotroph Lateral Scler Other Motor Neuron Disord (accepted in ALS and other MND).
  • Airlie House World Federation of Neurology. Guidelines for ALS clinical trialsJ Neurol Sci 1995; 129: 1–10.
  • Miller RG, Munsat TL, Swash M, Brooks BR. Consensus guidelines for the design and implementation of clinical trials in ALS2nd Airlie House Workshop 1998 (available from http:// wfnals.org).
  • Brooks BR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosisJ Neurol Sci 1994; 124 (suppl): 96–107.
  • European Coal and Steel Community, Quanjer PH. Working Party ‘‘Standardization of Lung Function Tests’’In: Chapter 7: Summary equations of reference values. Bull Eur Physiopathol Respir 1983; 19 (suppl 5): 45–51.
  • Hochberg Y. A sharper Bonferroni procedure for multiple tests of significanceBiometrika 1988; 75(4): 800–802.
  • Cox DR. Regression models and life-tablesJ R Stat Soc [B] 1972; 34: 187–220.
  • O’Brien PC. Procedures for comparing samples with multiple endpointsBiometrics 1984; 40: 1079–1084.
  • Committee for Proprietary Medicinal Products (CPMP). Points to consider on clinical investigation of medicinal products for the treatment of amyotrophic lateral sclerosis (ALS)EMEA 2000, Oct. 19, London: 1–4.
  • Miller RG, Rosenberg JA, Gelinas D et al. Practice parameter: the care of the patient with amyotrophic lateral sclerosis (an evidence-based review)Neurology 1999; 52: 1311–1323.
  • Goldblatt D, Greenlaw J. Starting and stopping the ventilator for patients with amyotrophic lateral sclerosisNeurol Clin 1989; 7(4): 789–806.
  • Sanjak M, Salachas F, Frija-Orvoen F et al. Prospective quality control of vital capacity (VC) as primary endpoint in interna- tional multi-centre therapeutic trial of SR57746A (xaliproden) in amyotrophic lateral sclerosis (ALS)Amyotr Lat Scler 2000; 1(supp 3): 59–60.
  • Meininger V, Bensimon G, Lacomblez L, Salachas F. Natural history of amyotrophic lateral sclerosisIn: Serratrice G and Munsat T, eds. Pathogenesis and Therapy of Amyotrophic Lateral Sclerosis, Advances in Neurology, vol. 28. Philadelphia: Lippincott-Raven Publishers, 1995: 199–207.
  • Stambler N, Charatan M, Cedarbaum JM. Prognostic indicators of survival in ALS. ALS CNTF Treatment Study GroupNeurology 1998; 50(1): 66–72.
  • Bourke SC, Shaw PJ, Gibson GJ. Respiratory function vs. sleep- disordered breathing as predictors of QOL in ALSNeurology 2001; 57: 2040–2044.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.